Ardelyx, Inc. (ARDX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Michael G. Raab
|
President, CEO & Director | 1.43M | 412.5k | 1965 |
|
Ms. Sue Hohenleitner
|
Chief Financial Officer | 507.35k | -- | 1971 |
|
Dr. John Bishop Ph.D.
|
Chief Technical & Quality Officer | 599.51k | -- | 1962 |
|
Mr. Joseph Reilly
|
Senior VP of Finance & Principal Accounting Officer | -- | -- | 1974 |
|
Ms. Lisa M. Caperelli
|
Senior Vice President of Investor Relations and Corporate Communications | -- | -- | -- |
|
Ms. Felecia W. Ettenberg
|
Chief Legal Officer | -- | -- | 1971 |
|
Mr. James P. Brady
|
Chief Human Resources Officer | -- | -- | 1971 |
|
Dr. Laura A. Williams M.D., M.P.H.
|
Chief Patient Officer Emeritus | 739.13k | 669.9k | 1963 |
|
Mr. Mike Kelliher
|
Chief Business Officer | 622.5k | -- | 1977 |
|
Dr. Rajani Dinavahi M.D.
|
Chief Medical Officer | -- | -- | 1976 |
Ardelyx, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 489
Description
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
November 3, 2026 at 9:00 PM UTC
Ardelyx, Inc. Earnings Date
